Raymond T. Bartus

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

Jeffrey H. Kordower, C. Warren Olanow, Hemraj B. Dodiya et al. · Brain · 2013 · 1.3K citations · Full text

Disease Duration, Dopaminergic Markers, Dopamine Loss +22

Age‐associated memory impairment: Proposed diagnostic criteria and measures of clinical change — report of a national institute of mental health work group

Thomas H. Crook, Raymond T. Bartus, Steven H. Ferris et al. · Developmental Neuropsychology · 1986 · 935 citations

Neurodevelopmental Disorders, Neuropsychological Functioning, Neuropsychology +14

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

William J. Marks, Raymond T. Bartus, João Siffert et al. · The Lancet Neurology · 2010 · 669 citations

Neurodegenerative Diseases, Neurology, Gene Delivery +4

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

William J. Marks, Jill L. Ostrem, L. Verhagen et al. · The Lancet Neurology · 2008 · 581 citations

Neurodegenerative Diseases, Idiopathic Parkinson, Medicine +4

The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions

Raymond T. Bartus, Reginald L. Dean, Michael J. Pontecorvo et al. · Annals of the New York Academy of Sciences · 1985 · 385 citations · Full text

Neuropsychology, Neurotransmitter, Peripheral Nervous System +16